Skip to main content
Eric Nuermberger, MD, Infectious Disease, Baltimore, MD

Eric Lee Nuermberger MD

Infectious Disease•Baltimore, MD

Associate Professor of Medicine, Johns Hopkins University School of Medicine

Join to View Full Profile

  • 1800 Orleans StreetBaltimore, MD 21287

  • Phone+1 410-955-5000

  • Fax+1 410-955-5001

Dr. Nuermberger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Nuermberger's Full ProfileAlready have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Infectious Disease, 1999 - 2003
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1996 - 1999
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 1996

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2000 - 2025
  • FL State Medical License
    FL State Medical License 2015 - 2022
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Publications & Presentations

PubMed

Press Mentions

  • New Consortium Receives NIH Grant to Accelerate Development of Effective TB Treatments
    New Consortium Receives NIH Grant to Accelerate Development of Effective TB TreatmentsJuly 10th, 2024
  • Tip Sheet: Johns Hopkins Researchers Present at Annual CROI Meeting
    Tip Sheet: Johns Hopkins Researchers Present at Annual CROI MeetingMarch 1st, 2018
  • Africa: Cure at Last for Multi-Drug-Resistant TB
    Africa: Cure at Last for Multi-Drug-Resistant TBMarch 31st, 2017

Grant Support

  • Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) ConsortiumUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
  • Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosisJOHNS HOPKINS UNIVERSITY2021–2026
  • Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosisJOHNS HOPKINS UNIVERSITY2021–2026
  • Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosisJOHNS HOPKINS UNIVERSITY2021–2026
  • Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosisJOHNS HOPKINS UNIVERSITY2021–2026
  • Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosisJOHNS HOPKINS UNIVERSITY2021–2026
  • Development of novel penems for drug-resistant tuberculosisJOHNS HOPKINS UNIVERSITY2018–2024
  • Advancing New Drug Regimens For Mdr/Xdr TBNational Institute Of Allergy And Infectious Diseases2010–2011
  • Defining Moxifloxacin As A First-Line TB DrugNational Institute Of Allergy And Infectious Diseases2004–2008

External Links

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Eric Nuermberger, Dr. Eric Nuermberger, MD, Dr. E Nuermberger, Dr. Eric Lee Nuermberger